![Daniel Long](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Daniel Long
Corporate Officer/Principal bij
SEPTERNA, INC.
Vermogen: 3 M $ op 31-05-2026
Profiel
Daniel Long currently works at Septerna, Inc., as Senior Vice President-Drug Discovery from 2021.
Dr. Long also formerly worked at Theravance Biopharma, Inc., as Vice President & Head-Medical Chemistry & Biology from 2001 to 2021.
Dr. Long received his undergraduate degree, graduate degree, and doctorate degree from the University of Oxford.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
SEPTERNA, INC. 0,21% | 22-06-2026 | 96.412 ( 0,21% ) | 3 M $ | 31-05-2026 |
Actieve functies van Daniel Long
| Bedrijven | Functie | Begin |
|---|---|---|
| SEPTERNA, INC. | Corporate Officer/Principal | 01-12-2021 |
Eerdere bekende functies van Daniel Long
| Bedrijven | Functie | Einde |
|---|---|---|
| THERAVANCE BIOPHARMA, INC. | Corporate Officer/Principal | 01-12-2021 |
Opleiding van Daniel Long
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
26
Eerstegraads connecties
3
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 3 |
|---|---|
University of Oxford
 University of Oxford Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Theravance Biopharma, Inc.
 Theravance Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Engages in the discovery, development and commercialization of human therapeutics products for respiratory diseases | Health Technology |
Septerna, Inc.
 Septerna, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biotechnology company that discovers and develops G protein-coupled receptor oral small molecule products for the treatment of hypoparathyroidism | Health Technology |
